Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Navigating through the changing treatment landscape of advanced prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.05.18
Views: 2013

Prof Heather Payne, Dr Luis Martinez-Piñeiro, Prof Woet Gianotten, Prof Álvaro Pinto and Prof Anders Bjartell

Professor Heather Payne is joined by Dr Luis Martinez-Piñeiro, Professor Woet Gianotten, Dr Álvaro Pinto and Professor Ander Bjartell at the 13th Prostate Cancer Debate in Madrid.

The discussion opens with a conversation around the definition of advanced prostate cancer and the importance of taking into consideration disease volume and risk when categorising patients.

The panel discuss hormone sensitive prostate cancer and the latest advancements in the treatment of these patients. Dr Pinto talks around the lack of reliable biomarkers meaning that clinical factors and patient preference play a significant role in treatment selection.

The increased awareness of patients with non-metastatic castration resistant prostate cancer (nmCRPC) is also discussed and the ways in which this patient group are identified and characterised. The panel feel that results from the PROSPER and SPARTAN trials have provided more treatment opportunities for these patients; with PFS2 data highlighting the importance of subsequent treatments and the need for standardisation of monitoring this patient group.

Professor Gianotten also discusses the interplay between cancer and sexual relationships and the difference between sex and sexuality highlighting the need for a holistic approach to cancer therapy.

Disease volume and risk
Abiraterone or docetaxel in hormone sensitive disease?
PROSPER and SPARTAN trials in nmCRPC
New endpoints in daily practice and clinical trials
Sexual function and sexuality

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation